Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Accured Expenses (2022 - 2025)

Taysha Gene Therapies' Change in Accured Expenses history spans 4 years, with the latest figure at $5.0 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 1070.09% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $3.7 million, up 204.99%, while the annual FY2024 figure was -$1.4 million, 77.36% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $5.0 million at Taysha Gene Therapies, up from $732000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.0 million in Q3 2025 and bottomed at -$7.9 million in Q2 2022.
  • The 4-year median for Change in Accured Expenses is -$538000.0 (2022), against an average of -$893733.3.
  • The largest annual shift saw Change in Accured Expenses crashed 2453.04% in 2023 before it skyrocketed 1070.09% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at -$747000.0 in 2022, then tumbled by 170.01% to -$2.0 million in 2023, then soared by 105.26% to $106000.0 in 2024, then soared by 4624.53% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Change in Accured Expenses are $5.0 million (Q3 2025), $732000.0 (Q2 2025), and -$2.1 million (Q1 2025).